KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells $292,598.28 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 10,926 shares of the stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $26.78, for a total transaction of $292,598.28. Following the completion of the sale, the chief executive officer owned 479,989 shares in the company, valued at $12,854,105.42. This represents a 2.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV opened at $26.77 on Friday. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of -7.74 and a beta of -0.12. The firm’s 50 day simple moving average is $22.14 and its 200 day simple moving average is $17.76. The company has a debt-to-equity ratio of 8.18, a current ratio of 5.17 and a quick ratio of 5.10. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.83 and a fifty-two week high of $26.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The company had revenue of $40.86 million for the quarter, compared to analyst estimates of $39.03 million. As a group, sell-side analysts forecast that KalVista Pharmaceuticals, Inc. will post -0.96 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of KALV. Tudor Investment Corp ET AL bought a new position in shares of KalVista Pharmaceuticals during the third quarter worth about $24,360,000. Vestal Point Capital LP raised its holdings in shares of KalVista Pharmaceuticals by 152.0% in the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after purchasing an additional 1,140,000 shares during the last quarter. Parkman Healthcare Partners LLC raised its holdings in shares of KalVista Pharmaceuticals by 155.5% in the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after purchasing an additional 1,055,940 shares during the last quarter. Ameriprise Financial Inc. raised its holdings in shares of KalVista Pharmaceuticals by 2,258.6% in the second quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock valued at $10,685,000 after purchasing an additional 905,053 shares during the last quarter. Finally, Elmind Capital LP acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at approximately $12,941,000.

Analyst Upgrades and Downgrades

KALV has been the topic of a number of analyst reports. Leerink Partners downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Wall Street Zen downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, April 21st. HC Wainwright downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $37.00 to $27.00 in a report on Friday, May 1st. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st. Finally, JonesTrading downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. Three research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, KalVista Pharmaceuticals has an average rating of “Hold” and a consensus price target of $30.60.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.